Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:ATRA NASDAQ:GNFT NASDAQ:MGTX NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsATRAAtara Biotherapeutics$14.32+1.4%$13.29$5.01▼$18.70$100.57M0.2599,269 shs25,681 shsGNFTGENFIT$4.29-0.3%$4.07$2.55▼$6.03$214.25M1.188,170 shs1,508 shsMGTXMeiraGTx$8.73-0.2%$7.92$4.55▼$9.44$701.52M1.34494,563 shs290,988 shsREPLReplimune Group$8.50+1.0%$5.29$2.68▼$17.00$663.12M0.424.53 million shs907,687 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-85.61%ATRAAtara Biotherapeutics-3.49%-7.35%+8.87%+21.93%+66.71%GNFTGENFIT-0.23%+3.49%+18.11%+11.10%-24.47%MGTXMeiraGTx+0.11%+7.63%+7.36%+4.54%+49.57%REPLReplimune Group+1.45%+80.30%+94.46%+167.30%-29.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsATRAAtara Biotherapeutics$14.32+1.4%$13.29$5.01▼$18.70$100.57M0.2599,269 shs25,681 shsGNFTGENFIT$4.29-0.3%$4.07$2.55▼$6.03$214.25M1.188,170 shs1,508 shsMGTXMeiraGTx$8.73-0.2%$7.92$4.55▼$9.44$701.52M1.34494,563 shs290,988 shsREPLReplimune Group$8.50+1.0%$5.29$2.68▼$17.00$663.12M0.424.53 million shs907,687 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-85.61%ATRAAtara Biotherapeutics-3.49%-7.35%+8.87%+21.93%+66.71%GNFTGENFIT-0.23%+3.49%+18.11%+11.10%-24.47%MGTXMeiraGTx+0.11%+7.63%+7.36%+4.54%+49.57%REPLReplimune Group+1.45%+80.30%+94.46%+167.30%-29.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideATRAAtara Biotherapeutics 2.67Moderate Buy$21.0046.65% UpsideGNFTGENFIT 2.00Hold$7.0063.36% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.67194.01% UpsideREPLReplimune Group 2.45Hold$11.0029.35% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, REPL, APTO, GNFT, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ATRAAtara BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/21/2025MGTXMeiraGTxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$29.0010/20/2025REPLReplimune GroupLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/20/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$13.0010/20/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$11.0010/20/2025REPLReplimune GroupLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$3.00 ➝ $13.0010/20/2025REPLReplimune GroupWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$4.00 ➝ $18.0010/14/2025GNFTGENFITWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/14/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ATRAAtara BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$188.67M0.53N/AN/A($16.89) per share-0.85GNFTGENFIT$76.77M2.79$0.07 per share61.48$1.50 per share2.86MGTXMeiraGTx$33.28M21.10N/AN/A$0.87 per share10.03REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/AMGTXMeiraGTx-$147.79M-$2.04N/A22.97N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)Latest ATRA, REPL, APTO, GNFT, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025MGTXMeiraGTx-$0.51N/AN/AN/A$7.71 millionN/A11/11/2025Q3 2025ATRAAtara Biotherapeutics-$0.83N/AN/AN/A$2.74 millionN/A11/11/2025Q2 2026REPLReplimune Group-$0.86N/AN/AN/A$0.50 millionN/A8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05ATRAAtara BiotherapeuticsN/A1.701.70GNFTGENFIT0.093.743.74MGTXMeiraGTx26.290.880.88REPLReplimune Group0.216.946.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%GNFTGENFIT2.24%MGTXMeiraGTx67.48%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%ATRAAtara Biotherapeutics4.00%GNFTGENFIT4.20%MGTXMeiraGTx7.50%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableATRA, REPL, APTO, GNFT, and MGTX HeadlinesRecent News About These CompaniesThe Best AI for Picking Stocks, Ranked by Performance (REPL)...October 23 at 2:38 PM | marketbeat.comReplimune Group FY2027 EPS Decreased by Leerink PartnrsOctober 23 at 8:02 AM | marketbeat.comReplimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?October 22 at 3:54 PM | finance.yahoo.comWedbush Issues Positive Outlook for Replimune Group EarningsOctober 22 at 8:20 AM | marketbeat.comBarclays Keeps Their Hold Rating on Replimune Group (REPL)October 22 at 7:42 AM | theglobeandmail.comKLP Kapitalforvaltning AS Has $70,000 Stock Holdings in Replimune Group, Inc. $REPLOctober 22 at 5:01 AM | defenseworld.netDJP Morgan Upgrades Replimune Group (REPL)October 21 at 4:01 PM | msn.comWedbush Upgrades Replimune Group (REPL)October 21 at 11:00 AM | msn.comReplimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory BreakthroughOctober 21 at 11:00 AM | blockonomi.comReplimune bounces back on FDA acceptance of BLAOctober 21 at 11:00 AM | thepharmaletter.comTA Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial ResultsOctober 21 at 11:00 AM | finance.yahoo.comLeerink Partnrs Upgrades Replimune Group (NASDAQ:REPL) to "Strong-Buy"October 21 at 7:35 AM | marketbeat.comReplimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)October 21 at 7:30 AM | seekingalpha.comReplimune Group, Inc. $REPL Shares Bought by TD Asset Management IncOctober 21 at 3:46 AM | marketbeat.comWhy Replimune Stock Was Soaring TodayOctober 20, 2025 | fool.comReplimune Group (NASDAQ:REPL) Upgraded by Piper Sandler to "Overweight" RatingOctober 20, 2025 | marketbeat.comPromising Biotech Stocks To Follow Now - October 20thOctober 20, 2025 | marketbeat.comJPMorgan Chase & Co. Upgrades Replimune Group (NASDAQ:REPL) to "Neutral"October 20, 2025 | marketbeat.comReplimune's FDA BLA Resubmission for RP1: A New Hope for Advanced Melanoma TreatmentOctober 20, 2025 | sohu.comSWhat Is Driving Replimune Stock’s 98% Surge Today?October 20, 2025 | msn.comReplimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst UpgradeOctober 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRA, REPL, APTO, GNFT, and MGTX Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara Biotherapeutics NASDAQ:ATRA$14.32 +0.20 (+1.42%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.GENFIT NASDAQ:GNFT$4.28 -0.02 (-0.35%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MeiraGTx NASDAQ:MGTX$8.73 -0.02 (-0.23%) As of 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Replimune Group NASDAQ:REPL$8.50 +0.08 (+1.00%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
